Ceftiofur (CEF) sodium is a third-generation broad-spectrum cephalosporin commonly used in an extra-label manner in dogs for the treatment of respiratory and urinary system infections. To contribute to the literature supporting CEF use in companion animals, we have developed a compartmental, nonlinear mixed-effects (NLME) model of CEF pharmacokinetics in dogs (PK). We then used the mathematical model to predict (via Monte Carlo simulation) the duration of time for which plasma concentrations of CEF and its pharmacologically active metabolites remained above minimum inhibitory concentrations (respiratory tract Escherichia coli spp). Twelve healthy beagle dogs were administered either 2.2 mg/kg ceftiofur-sodium (CEF-Na) intravenously (I.V) or 2.2 mg/kg CEF-Na subcutaneously (S.C). Plasma samples were collected over a period of 72 hours post-administration. To produce a measurement of total CEF, both CEF and CEF metabolites were derivatized into desfuroylceftiofur acetamide (DCA) before analysis by UPLC-MS/MS. No adverse effects were reported after I.V or S.C dosing. The NLME PK models were parameterized using the stochastic approximation expectation maximization algorithm as implemented in Monolix 2018R2. A twocompartment mammillary model with first-order elimination and first-order S.C absorption best described the available kinetic data. Final parameter estimates indicate that CEF has a low systemic clearance (0.25 L/h/ kg) associated with a low global extraction ratio E = 0.02) and a moderate volume of distribution (2.97 L/kg) in dogs. The absolute bioavailability after S.C administration was high (93.7%). Gender was determined to be a significant covariate in explaining the variability of S.C absorption. Our simulations predicted that a dose of 2.2 mg/kg CEF-Na S.C would produce median plasma concentrations of CEF of at least 0.5 µg/mL (MIC50) for approximately 30 hours.
, camels [9] , goats [10] , horses [11], sheep [12] , swine [1] , alpacas [13] , and rabbits [14] .
The PK of subcutaneous (S.C) CEF crystalline-free acid S.C [15] as well as the PK of CEF-Na S.C [16] 48 have been previously reported in dogs. However, no detailed description of CEF-Na disposition 49 kinetics after intravenous (I.V) dosing is currently available in dogs, which prevents a rigorous 50 assessment of absolute bioavailability in this species. And, despite common off-label use of CEF-Na 51 in veterinary clinics for canine respiratory disease, no formulation is currently approved for use in derivatization with iodoacetamide to DCA and total CEF equivalent concentration (measured as from 100 to 5,000 ng/mL. The inter-day and intra-day coefficients of variation -using 200, 1000, and 95 4000 ng/mL standards -were all below 7.58%, while the mean recoveries ranged from 82.15 to 96 119.44%. All analyses complied with established guidelines on bioanalytical method validation [20] .
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NLME Model Building and Evaluation
98
No outliers were identified after initial data exploration in Monolix datxplore (2018R2, Lixoft,
99
France), such that all data could be pooled together for model building. CEF plasma concentration 100 time-courses from I.V and S.C dosing were analyzed simultaneously using the stochastic 101 approximation expectation maximization algorithm as implemented in Monolix 2018R2 (Lixoft,
102
France). Individual model parameters were obtained by using the full posterior of the conditional 103 distribution. NLME models were written as described by Sheiner and Ludden [21, 22] : where is an independent random variable distributed in a standard normal distribution i.e.
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. Each individual parameter was modeled as a combination of the population 114 mean (i.e. ) and log-normally distributed error i.e. .
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Convergence of the SAEM algorithm was evaluated by inspection of the stability of the fixed-and 
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In the first set of simulations, we simulated a population of 500 females and 500 females and virtually 152 administered CEF-Na at 2.2 mg/kg S.C. Then, we used the PK data from this simulation to produce 153 prediction distributions of CEF between 0 and 40 hours.
154
In the second set of simulations, we simulated the median CEF PK of male and female dogs after S.C 155 dosing with 1 to 5 mg/kg (in steps of .1 mg/kg) of CEF-Na. Using this second simulation set, we were 156 able to calculate the median τ50 and median τ90 for both males and females as a function of CEF-Na based on standard goodness-of-fit diagnostic plots, precision of parameter estimates (RSE), as well identified and subsequently included in the structure of the statistical model ( , sex as a significant covariate on CEF subcutaneous absorption rate (P ≤ 0.01). Gender was therefore 177 included in the final model structure, using the following relationship: The prediction distribution of CEF equivalents over time after 2.2 mg/kg CEF-Na S.C administration percentiles of the simulated population (Figure 5A) . Also, because male dogs had a higher estimated 228 CEF absorption rate than females, their peak exposure (i.e. Cmax) was predicted to be greater than in 229 female dogs.
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Results from our model-based simulations suggest that after one dose of 2.5 mg/kg CEF-Na S.C, 231 ceftiofur concentrations would remain above the MIC50 threshold (0.5 µ g/mL) for almost 1.5 days in 232 both male and female dogs (Figure 5B) .
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In contrast, our predictions of median τ90 as a function of dosage indicate that even when 234 administered at unrealistically large doses of CEF-Na S.C (~ 5 mg/kg), CEF concentrations would 235 remain above MIC90 levels for no more than 8 hours (Figure 5C ). 
